News | Congenital Heart | October 28, 2016

Fetal Surgery Successfully Removes Life-Threatening Tumor Connected to Heart

Fetal medicine experts at Children’s Hospital of Philadelphia report first successful case of in-utero surgery for heart-threatening mass

CHOP, Children's Hospital of Philadelphia, prenatal heart surgery, tumor removal, intrapericardial teratoma

Tucker Roussin, 3, is the first survivor of fetal surgery for a life-threatening tumor connected to his heart. Fetal medicine experts at Children's Hospital of Philadelphia successfully removed this tumor. Credit: Children’s Hospital of Philadelphia.

October 28, 2016 — For the first time, fetal medicine experts have performed prenatal heart surgery to remove a life-threatening tumor, called intrapericardial teratoma. The patient, who underwent the operation at 24 weeks of gestation while in his mother’s womb, is now a healthy three-year-old preschooler.

“We have shown that we can accurately diagnose and provide a prognosis for this rare condition in utero, as well as perform fetal surgery,” said co-study leader Jack Rychik, M.D., director of the Fetal Heart Program at the Children’s Hospital of Philadelphia (CHOP).

Rychik, along with co-study leader Nahla Khalek, M.D., of the Center for Fetal Diagnosis and Treatment (CFDT) at CHOP, and colleagues recently published their findings online in the American Journal of Obstetrics and Gynecology.

The research team, from CHOP and the Perelman School of Medicine at the University of Pennsylvania, reported a case series of eight fetuses with suspected intrapericardial teratoma seen at CHOP between 2009 and 2015.

Intrapericardial teratoma is an extremely rare, rapidly growing tumor that can be detected during the fetal period. Arising in the pericardium, the sac surrounding the heart, it is lethal if untreated. The current prenatal strategy is to drain pericardial fluid to buy time for the fetus to grow to a viable gestational age, followed by surgery to remove the teratoma shortly after delivery. However, rapid prenatal growth of the tumor, along with fluid around the heart, which inflicts dangerous pressure on the heart, lead to disruption of normal fetal circulation and fetal death.

Therefore, an ideal treatment is to perform surgery prenatally, before cardiac dysfunction occurs. The CHOP team is the first to perform this prenatal surgery resulting in a healthy live born neonate.

The case series in the current study covers eight fetuses evaluated for suspected intrapericardial teratoma at CHOP, two of whom were found to have other types of heart-related tumors. Of the six cases with intrapericardial teratoma, two survived, both following surgery. One underwent open fetal surgery at 24 weeks gestation, while the other underwent successful EXIT (ex utero intrapartum treatment) procedure at 31 weeks gestation. In the EXIT procedure, surgeons partially deliver the baby through an incision made in the mother’s uterus and perform surgery while the baby remains connected to the placenta.

Of the four cases of intrapericardial teratoma who died, none underwent fetal surgery, in some cases because referral was late and the fetuses were too sick to benefit from intervention.

“Managing this type of teratoma presenting before birth is a challenge, but we show that survival with good outcome may be possible in some patients,” said Rychik. “It was the ability to bring so many different disciplines to the table that made us confident enough to take the leap to offer in-utero surgery on a fetal heart as a viable option,” added Rychik.

“The current era offers technological advantages, such as improved prenatal imaging, improved cardiovascular surveillance through fetal echocardiography, and fetal surgery techniques,” said co-study leader Nahla Khalek, M.D., a maternal-fetal medicine specialist in the CFDT. “A crucial factor is implementing treatment before fetal heart failure occurs. Our findings underscore the importance of promptly referring these cases to a multidisciplinary fetal therapy center during the optimal window of opportunity for both the fetus and mother.”

“Removing a tumor from a baby’s heart in-utero present significant risks for both the mother and the baby. Timing and coordination early in the illness is vitally important,” added co-author Holly L. Hedrick, M.D., attending pediatric and fetal surgeon in the CFDT. CHOP’s fetal surgeons, who have performed more than 1,350 in utero surgeries, are highly experienced in reducing those risks; their work has helped make complex prenatal surgery an option for a growing number of fetuses diagnosed with birth defects.

“The pioneering fetal surgery to remove a tumor from a baby’s heart is an incredible breakthrough and an innovation in the care that can be provided to a family who receives this devastating diagnosis,” said co-author J. William Gaynor, M.D., a pediatric cardiothoracic surgeon at CHOP. “We need to constantly ask new questions and take our work in new directions by bringing the top experts in their fields to counsel and provide state-of-the-art care to our mothers and babies.”

For more information:

Related Content

Beta Blocker Shows Mixed Results in Protecting Against Chemo-Induced Heart Damage
News | Cardio-oncology | March 14, 2018
After six months of follow-up, women newly diagnosed with breast cancer who were given the beta blocker carvedilol to...
Heart Failure More Likely for Some Breast Cancer and Lymphoma Survivors
News | Cardio-oncology | March 01, 2018
March 1, 2018 –  Patients who were treated for breast cancer or lymphoma are more than three times at risk for develo
Cell phone emissions cause cardiac tumors in males rats.
News | Cardio-oncology | February 06, 2018
High exposure to radiofrequency radiation (RFR) in rodents resulted in tumors in tissues surrounding nerves in the...
Videos | Cardio-oncology | February 01, 2018
American Heart Association (AHA) released a scientific statement Feb.
Laxmi Mehta, M.D., reviews an echocardiogram at The Ohio State Wexner Medical Center for a cardio-oncology cancer patient to look for heart damage caused by chemotherapy or radiation therapy.

Laxmi Mehta, M.D., reviews an echocardiogram at The Ohio State Wexner Medical Center. She is calling for more research and collaboration to examine the link between heart disease and breast cancer to develop new treatments and preventative measures.

Feature | Cardio-oncology | February 01, 2018
February 1, 2018 – Heart disease and breast cancer are two of the most prevalent diseases among women in the United S
Treatment of Heart Attack Patients Depends on Cancer History
News | Cardio-oncology | September 26, 2017
Treatment of heart attack patients depends on their history of cancer, according to research published recently in...
Pediatric echo protocols for cardio-oncology cardiotoxicity exams.
News | Cardio-oncology | June 15, 2017
 June 15, 2017 – Children who have suffered from cancer may also have lasting side effects from the drugs used in the
Strain Imaging Improves Cardiac Surveillance of Certain Breast Cancer Patients
News | Cardio-oncology | May 03, 2017
Epsilon Imaging Inc. announced a research study using EchoInsight was presented at the American College of Cardiology (...
Overlay Init